MarketBeat | Real-Time Financial News and Analysis

Open Main Menu Open Sidebar

Osiris Therapeutics Company Profile (NASDAQ:OSIR)

Consensus Ratings for Osiris Therapeutics (NASDAQ:OSIR) (?)
Ratings Breakdown: 1 Sell Rating(s), 1 Buy Rating(s)
Consensus Rating:Hold (Score: 2.00)
Consensus Price Target: $16.00 (212.50% upside)

Analysts' Ratings History for Osiris Therapeutics (NASDAQ:OSIR)
Show:
DateFirmActionRatingPrice TargetActions
3/16/2016Brean CapitalReiterated RatingSell$4.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
2/2/2016Piper JaffrayReiterated RatingBuyView Rating Details  Tweet This Rating  Share This Rating on StockTwits
9/16/2014R. F. LaffertyInitiated CoverageBuy$19.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
(Data available from 6/30/2014 forward)
Earnings History for Osiris Therapeutics (NASDAQ:OSIR)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallActions
4/7/2016        
11/6/2015Q315$0.06($0.02)$25.40 million$24.30 millionViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
8/5/2015Q215$0.06$0.03$23.60 million$23.70 millionViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
5/8/2015Q115$0.04$18.40 million$21.00 millionViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
3/5/2015Q414$0.05$0.03$18.53 million$19.50 millionViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
11/7/2014Q314($0.01)$0.02$14.80 million$17.20 millionViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
8/7/2014Q214$0.16($0.04)$11.00 million$13.30 millionViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
5/12/2014($0.08)($0.02)ViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
3/5/2014Q413$0.65$0.11$7.50 million$8.10 millionViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
11/1/2013Q313($0.10)($0.05)$6.70 million$6.88 millionViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
8/5/2013Q2 2013($0.09)($0.11)$4.35 million$5.29 millionViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
5/7/2013Q1 2013($0.09)($0.08)$3.53 million$4.06 millionViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
11/5/2012Q312($0.14)($0.09)$1.89 million$2.15 millionViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
(Data available from 1/1/2011 forward)
Earnings Estimates for Osiris Therapeutics (NASDAQ:OSIR)
No earnings estimates for this company have been tracked by MarketBeat.com

Dividend History for Osiris Therapeutics (NASDAQ:OSIR)
AnnouncedPeriodAmountYieldEx-Dividend DateRecord DatePayable DateShare
9/17/2015special$0.209/14/20159/16/20159/30/2015Tweet This Announcement  Share This Announcement on StockTwits
9/17/2015special$0.2010/14/201510/16/201510/30/2015Tweet This Announcement  Share This Announcement on StockTwits
(Data available from 1/1/2013 forward)
Insider Trading History for Osiris Therapeutics (NASDAQ:OSIR)
Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionActions
5/27/2014Matthew Paul NeumayerInsiderSell3,750$16.10$60,375.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
5/21/2014Philip Jacoby, Jr.CFOSell15,947$15.43$246,062.21View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
3/14/2014Michelle Leroux WilliamsInsiderSell61,934$14.09$872,650.06View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
11/25/2013Philip Jacoby, Jr.CFOSell18,372$15.99$293,768.28View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
11/15/2013Michelle Leroux WilliamsInsiderSell24,500$15.50$379,750.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
8/20/2013Matthew Paul NeumayerInsiderSell11,375$19.75$224,656.25View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
(Data available from 1/1/2013 forward)
Latest Headlines for Osiris Therapeutics (NASDAQ:OSIR)
DateHeadline
06/29/16 05:36 PMOSIRIS THERAPEUTICS : Change in Directors or Principal Officers, Financial Statements and Exhibits (form 8-K/A)
06/29/16 04:03 PMOSIRIS THERAPEUTICS, INC. Files SEC form 8-K/A, Change in Directors or Principal Officers, Financial Statements and E -
06/27/16 05:38 PMStock Volatility in Review: Osiris Therapeutics, Inc. (NASDAQ:OSIR) - Engelwood Daily
06/27/16 05:38 PMOsiris Therapeutics MD (NASDAQ:OSIR) Short Interest Decreased By 3.07% - Engelwood Daily
06/27/16 09:52 AMAre Analysts Bearish Osiris Therapeutics, Inc. (NASDAQ:OSIR) After Last Week? - Press Telegraph
06/25/16 05:09 PMOsiris Therapeutics Inc. (OSIR) Jumps 5.77% on June 23
06/25/16 09:24 AMOsiris Therapeutics Inc. (OSIR) Jumps 5.77% on June 23 - Equities.com
06/24/16 05:38 PMOsiris Therapeutics, Inc. (OSIR) Updated Price Targets - FTSE News
06/22/16 05:36 PMOsiris Therapeutics Inc. (OSIR) Jumps 5.32% on June 20
06/22/16 10:24 AMOsiris Therapeutics Inc. (OSIR) Jumps 5.32% on June 20 - Equities.com
06/20/16 05:30 PMWhy Making Dramatic Moves: Osiris Therapeutics, Inc. (NASDAQ:OSIR), BioScrip, Inc. (NASDAQ:BIOS), Yingli Green ... - KC Register
06/16/16 09:54 AMOsiris Therapeutics' stock falters amid executive shakeup, federal investigation
06/13/16 05:15 PMInvestor News: Investigation of Osiris Therapeutics, Inc. (NASDAQ:OSIR) over possible Wrongdoing
06/13/16 08:38 AMInvestor News: Investigation of Osiris Therapeutics, Inc. (NASDAQ:OSIR) over possible Wrongdoing - GroundReport
06/10/16 05:57 PMBRIEF-Osiris Therapeutics says names David Dresner interim CEO - Reuters
06/10/16 03:27 PMBRIEF-Osiris Therapeutics says names David Dresner interim CEO - * Says it has appointed David Dresner as interim president and chief executive officer
06/10/16 03:02 PMOSIRIS THERAPEUTICS, INC. Files SEC form 8-K, Change in Directors or Principal Officers -
06/06/16 05:37 PMInvestigation for Investors in Shares of Osiris Therapeutics, Inc. (NASDAQ:OSIR) over Potential Wrongdoing by ... - Digital Journal
06/02/16 06:04 PMWill Osiris Therapeutics Inc. (NASDAQ:OSIR) Survive The Legal Onslaught? - Scibility Media - Scibility MediaWill Osiris Therapeutics Inc. (NASDAQ:OSIR) Survive The Legal Onslaught?Scibility MediaAccording to Therapeutics, Inc. (NASDAQ: OSIR), it recently received a notification from the U.S. Attorney's office that it was being investigated and the investigation revolves around a criminal subject. It seems the company cannot accurately say what ...Osiris Therapeutics Inc (OSIR) Drops 11.73% on May 31Equities.comStock in a Downward Trend: Osiris Therapeutics, Inc. (NASDAQ:OSIR)Franklin IndependentOsiris Therapeutics, Inc. (NASDAQ:OSIR)'s Company Shares Increased 1.07% After Low VolatilityHNNSonoran Weekly Review -Benchmark Monitor -Business Wire (press release)all 7 news articles »
06/02/16 11:49 AMIMPORTANT SHAREHOLDER ALERT: Khang & Khang LLP Announces an Investigation of Claims against Osiris Therapeutics, Inc. and Advises Investors to Contact the Firm - [Business Wire] - Khang & Khang LLP announces that it is investigating claims of potential misrepresentations by Osiris Therapeutics, Inc. . The investigation focuses on whether the Company and its officers violated securities laws by issuing misleading information to investors.
06/02/16 08:40 AMOsiris Therapeutics Inc (OSIR) Drops 11.73% on May 31 - Equities.com - Scibility MediaOsiris Therapeutics Inc (OSIR) Drops 11.73% on May 31Equities.comOsiris Therapeutics Inc (OSIR) was one of the Russell 2000's biggest losers for Tuesday May 31 as the stock slid 11.73% to $5.01, a loss of $-0.665 per share. Starting at an opening price of $4.75 a share, the stock traded between $4.75 and $5.22 over ...Will Osiris Therapeutics Inc. (NASDAQ:OSIR) Survive The Legal Onslaught?Scibility MediaStock in a Downward Trend: Osiris Therapeutics, Inc. (NASDAQ:OSIR)Franklin IndependentOsiris Therapeutics, Inc. (NASDAQ:OSIR)'s Company Shares Increased 1.07% After Low VolatilityHNNSonoran Weekly Review -Business Wire (press release)all 7 news articles »
06/01/16 06:11 PMSHAREHOLDER ALERT: Bronstein, Gewirtz & Grossman, LLC Announces Investigation of Osiris Therapeutics, Inc. - PR Newswire (press release) - SHAREHOLDER ALERT: Bronstein, Gewirtz & Grossman, LLC Announces Investigation of Osiris Therapeutics, Inc.PR Newswire (press release)NEW YORK , June 1, 2016 /PRNewswire/ -- Attorney Advertising -- Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of the securities of Osiris Therapeutics, Inc. ("Osiris" or the "Company") (NasdaqGM: OSIR -News).and more »
06/01/16 10:08 AMSHAREHOLDER ALERT: Levi & Korsinsky, LLP Announces the Commencement of an Investigation Into Possible Securities Fraud Violations by Certain Officers and Directors of Osiris Therapeutics, Inc. -- OSIR - [Business Wire] - Levi & Korsinsky announces it has commenced an investigation of Osiris Therapeutics, Inc. concerning possible violations of federal securities laws.
06/01/16 09:00 AMSHAREHOLDER ALERT: Bronstein, Gewirtz & Grossman, LLC Announces Investigation of Osiris Therapeutics, Inc. - [PR Newswire] - NEW YORK , June 1, 2016 /PRNewswire/ -- Attorney Advertising -- Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of the securities of Osiris Therapeutics, ...
05/31/16 05:57 PMINVESTOR ALERT: Investigation of Osiris Therapeutics, Inc. Announced by Law Offices of Howard G. Smith - Business Wire (press release) - INVESTOR ALERT: Investigation of Osiris Therapeutics, Inc. Announced by Law Offices of Howard G. SmithBusiness Wire (press release)BENSALEM, Pa.--(BUSINESS WIRE)--Law Offices of Howard G. Smith announces an investigation on behalf of investors of Osiris Therapeutics, Inc. (“Osiris” or the “Company”) (NASDAQ: OSIR) concerning the Company and its officers' possible violations of ...Osiris Therapeutics, Inc. (NASDAQ:OSIR)'s Company Shares Increased 1.07% After Low VolatilityHNNall 1 news articles »
05/29/16 04:00 PMAre Analysts Bullish Osiris Therapeutics, Inc. (NASDAQ:OSIR) After Last Week? - HNN - Are Analysts Bullish Osiris Therapeutics, Inc. (NASDAQ:OSIR) After Last Week?HNNOut of 2 analysts covering Osiris Therapeutics (NASDAQ:OSIR), 1 rate it a “Buy”, 1 “Sell”, while 0 “Hold”. This means 50% are positive. Osiris Therapeutics has been the topic of 13 analyst reports since August 6, 2015 according to StockzIntelligence ...and more »
05/28/16 02:41 AMOSIRIS THERAPEUTICS, INC. : Other Events (form 8-K) - 05/10 OSIRIS THERAPEUTICS: to Present at the 26th European Wound Management Associati.. 05/02 OSIRIS THERAPEUTICS: Grafix Demonstrates Superior Clinical Outcomes Compared wi.. 05/02 OSIRIS THERAPEUTICS: Grafix Demonstrates Superior Clinical Outcomes ...
05/27/16 04:02 PMOSIRIS THERAPEUTICS, INC. Files SEC form 8-K, Other Events -
05/25/16 04:03 PMNew Broker Ratings For Osiris Therapeutics, Inc. (OSIR) - FTSE News - New Broker Ratings For Osiris Therapeutics, Inc. (OSIR)FTSE News03/16/2016 – Osiris Therapeutics, Inc. had its “sell” rating reiterated by analysts at Brean Capital. They now have a USD 4 price target on the stock. 11/30/2015 – Osiris Therapeutics, Inc. had its “buy” rating reiterated by analysts at Piper Jaffray ...and more »
05/22/16 03:38 PMWere Analysts Bullish Osiris Therapeutics, Inc. (NASDAQ:OSIR) This Week? - Wall Street Hints and News - Were Analysts Bullish Osiris Therapeutics, Inc. (NASDAQ:OSIR) This Week?Wall Street Hints and NewsOut of 2 analysts covering Osiris Therapeutics (NASDAQ:OSIR), 0 rate it a “Buy”, 0 “Sell”, while 0 “Hold”. This means NaN are positive. Osiris Therapeutics has been the topic of 13 analyst reports since August 6, 2015 according to StockzIntelligence ...and more »
05/21/16 07:25 AMBroker Roundup For Osiris Therapeutics, Inc. (OSIR) - Share Trading News - Broker Roundup For Osiris Therapeutics, Inc. (OSIR)Share Trading News03/16/2016 – Osiris Therapeutics, Inc. had its “sell” rating reiterated by analysts at Brean Capital. They now have a USD 4 price target on the stock. 11/30/2015 – Osiris Therapeutics, Inc. had its “buy” rating reiterated by analysts at Piper Jaffray ...Osiris Therapeutics MD (NASDAQ:OSIR) Shorted Shares Decreased By 0.7%The Postall 2 news articles »
05/19/16 09:47 AMMiMedx Goes After Osiris With Lawsuit -
05/17/16 07:53 AMMiMedx Group (MDXG) Files Lawsuit Against Osiris Therapeutics (OSIR) - StreetInsider.com - MiMedx Group (MDXG) Files Lawsuit Against Osiris Therapeutics (OSIR)StreetInsider.comMiMedx Group, Inc. (NASDAQ: MDXG), the leading regenerative medicine company utilizing human amniotic tissue and patent-protected processes to develop and market advanced products and therapies for the Wound Care, Surgical, Orthopedic, Spine, ...and more »
05/16/16 07:32 AMOsiris Provides Update Regarding NASDAQ Listing Matters - [at noodls] - COLUMBIA, Md.--(BUSINESS WIRE)-- Osiris Therapeutics, Inc. (NASDAQ:OSIR) (the 'Company'), today provided an update regarding the status of its compliance with the Listing Rules of the NASDAQ Stock Market ...
05/13/16 04:25 PMLatest Analyst Ratings For Osiris Therapeutics, Inc. (OSIR) - Share Trading News - Latest Analyst Ratings For Osiris Therapeutics, Inc. (OSIR)Share Trading News03/16/2016 – Osiris Therapeutics, Inc. had its “sell” rating reiterated by analysts at Brean Capital. They now have a USD 4 price target on the stock. 11/30/2015 – Osiris Therapeutics, Inc. had its “buy” rating reiterated by analysts at Piper Jaffray ...and more »
05/10/16 09:33 PMAre Analysts Bullish Osiris Therapeutics, Inc. (NASDAQ:OSIR) After Last Week? - B.O.D.Y Confidential - Are Analysts Bullish Osiris Therapeutics, Inc. (NASDAQ:OSIR) After Last Week?B.O.D.Y ConfidentialOut of 2 analysts covering Osiris Therapeutics (NASDAQ:OSIR), 1 rate it a “Buy”, 1 “Sell”, while 0 “Hold”. This means 50% are positive. Osiris Therapeutics has been the topic of 13 analyst reports since August 6, 2015 according to StockzIntelligence ...and more »
05/10/16 03:08 PMOsiris to Present at the 26th European Wound Management Association Conference - [at noodls] - 10 Clinical and Scientific Studies will be featured May 11- 13, 2016 in Bremen, Germany COLUMBIA, Md.--(BUSINESS WIRE)-- Osiris Therapeutics, Inc. (NASDAQ: OSIR), the leading cellular regenerative medicine ...
05/08/16 09:34 PMNext Weeks Broker Price Targets For Osiris Therapeutics, Inc. (OSIR) - Share Trading News - Next Weeks Broker Price Targets For Osiris Therapeutics, Inc. (OSIR)Share Trading News03/16/2016 – Osiris Therapeutics, Inc. had its “sell” rating reiterated by analysts at Brean Capital. They now have a USD 4 price target on the stock. 11/30/2015 – Osiris Therapeutics, Inc. had its “buy” rating reiterated by analysts at Piper Jaffray ...
05/07/16 02:34 AMOsiris Therapeutics, Inc.'s Trend Up, Especially After Today's Strong Session - B.O.D.Y Confidential - Osiris Therapeutics, Inc.'s Trend Up, Especially After Today's Strong SessionB.O.D.Y ConfidentialThe stock of Osiris Therapeutics, Inc. (NASDAQ:OSIR) is a huge mover today! The stock increased 4.63% or $0.22 during the last trading session, hitting $4.97. About 135,462 shares traded hands. Osiris Therapeutics, Inc. (NASDAQ:OSIR) has declined ...
05/06/16 09:29 PMOsiris Therapeutics Inc (OSIR) Drops 5.19% on May 05 - Equities.com - Osiris Therapeutics Inc (OSIR) Drops 5.19% on May 05Equities.comOsiris Therapeutics Inc (OSIR) was one of the Russell 2000's biggest losers for Thursday May 05 as the stock slid 5.19% to $4.75, a loss of $-0.26 per share. Starting at an opening price of $5.05 a share, the stock traded between $4.65 and $5.06 over ...and more »
05/05/16 09:46 PMOsiris Therapeutics Inc (OSIR) Drops 6% on May 04 - Equities.com - Osiris Therapeutics Inc (OSIR) Drops 6% on May 04Equities.comOsiris Therapeutics Inc (OSIR) was one of the Russell 2000's biggest losers for Wednesday May 04 as the stock slid 6% to $5.01, a loss of $-0.32 per share. Starting at an opening price of $5.31 a share, the stock traded between $5.00 and $5.45 over the ...and more »
05/04/16 09:25 PMOsiris Therapeutics Inc (OSIR) Drops 7.3% on May 03 - Equities.com - Osiris Therapeutics Inc (OSIR) Drops 7.3% on May 03Equities.comOsiris Therapeutics Inc (OSIR) was one of the Russell 2000's biggest losers for Tuesday May 03 as the stock slid 7.3% to $5.33, a loss of $-0.42 per share. Starting at an opening price of $5.68 a share, the stock traded between $5.29 and $5.93 over the ...and more »
05/03/16 11:25 AMMiMedx takes exception to Osiris Therapeutics' "real-world study" comparing Grafix to EpiFix -
05/03/16 08:30 AMMiMedx Comments on Flawed Osiris Data Review - [at noodls] - MARIETTA, Ga., May 3, 2016 /PRNewswire/ -- MiMedx Group, Inc. (NASDAQ: MDXG), the leading regenerative medicine company utilizing human amniotic tissue and patent-protected processes to develop and market ...
05/02/16 04:42 PMOsiris Therapeutics (OSIR) Says Grafix Demonstrates Superior Clinical Outcomes Compared with EpiFix - StreetInsider.com - Osiris Therapeutics (OSIR) Says Grafix Demonstrates Superior Clinical Outcomes Compared with EpiFixStreetInsider.comOsiris Therapeutics, Inc. (NASDAQ: OSIR), a leading cellular and regenerative medicine company, focused on developing and marketing products to treat conditions in wound care, orthopaedics and sports medicine, announces the results of A Retrospective, ...and more »
05/02/16 07:10 AMGrafix Demonstrates Superior Clinical Outcomes Compared with EpiFix in "Real World" Study - [at noodls] - Osiris completes comparative retrospective single center study of clinical outcomes achieved with Grafix and EpiFix COLUMBIA, Md.--(BUSINESS WIRE)-- Osiris Therapeutics, Inc. (NASDAQ: OSIR), a leading ...
05/02/16 07:05 AM8:05 am Osiris Therapeutics announces 'superior' clinical outcomes compared with EpiFix in 'Real World' study -
05/02/16 07:00 AMGrafix Demonstrates Superior Clinical Outcomes Compared with EpiFix in “Real World” Study - [Business Wire] - Osiris Therapeutics, Inc. , a leading cellular and regenerative medicine company, focused on developing and marketing products to treat conditions in wound care, orthopaedics and sports medicine, announces the results of A Retrospective, Single-Center, Non-Randomized, Cross-Sectional Comparative Effectiveness Study Evaluating Surface Area Reduction, Volume Reduction and Closure Rates in Acute and Chronic ...
04/08/16 11:08 AMOsiris Announces Further Expansion of Grafix Commercial Coverage - [at noodls] - Commercial Health Plan Lives Grew By 9.5 Million DuringMarch 2016 Alone COLUMBIA, Md.--(BUSINESS WIRE)-- Osiris Therapeutics, Inc. (NASDAQ: OSIR), a leading cellular and regenerative medicine company focused ...
03/16/16 03:00 PMOsiris Provides an Update on a Clinical Review by Blue Cross Blue Shield Association - [Business Wire] - Osiris Therapeutics, Inc. , a leading cellular and regenerative medicine company focused on developing and marketing products to treat conditions in wound care, orthopaedics and sports medicine, announced today that the Blue Cross Blue Shield Association has provided a positive review on Grafix® usage for individuals with diabetic lower-extremity ulcers.
About Osiris Therapeutics

Osiris Therapeutics logoOsiris Therapeutics, Inc. is a medical products company. The Company is focused on developing and marketing products in regenerative medicine, including bioengineering, stem cell research and viable tissue based products. The Company's offers products in orthopedics, sports medicine and wound care, including Cartiform, BIO4 and Grafix. Cartiform is a viable chondral allograft containing viable chondrocytes, chondrogenic growth factors, and extracellular matrix proteins within the intact architecture of healthy hyaline cartilage. BIO4 is a bone allograft that contains both viable cells and growth factors. It is a safe alternative to autograft that minimizes the potential for harvest site co-morbidities. Grafix is a cryopreserved placental membrane that preserves the native properties and inherent functionality of the tissue.

Industry, Sector and Symbol:
  • Sector: Healthcare
  • Industry: Biotechnology
  • Sub-Industry: Biotechnology
  • Exchange: NASDAQ
  • Symbol: OSIR
  • CUSIP: 68827R10
Key Metrics:
  • Previous Close: $5.12
  • 50 Day Moving Average: $5.10
  • 200 Day Moving Average: $6.57
  • P/E Ratio: 121.90
  • P/E Growth: 0.00
  • Market Cap: $176.39M
  • Current Quarter EPS Consensus Estimate: $0.08 EPS
Additional Links:
Osiris Therapeutics (NASDAQ:OSIR) Chart for Thursday, June, 30, 2016


            As Featured by CNBC As Featured by The Wall Street Journal As Featured by MarketWatch As Featured by The Boston Globe As Featured by StockTwits As Featured by Seeking Alpha